Advertisement

Topics

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015

01:04 EDT 5 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 515-page report is available in PDF from $2000.

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Head And Neck Cancer Squamous Cell Carcinoma Overview 11
Therapeutics Development 12
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 12
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 13
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 14
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 20
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 25
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 32
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 33
AbbVie Inc. 33
Acceleron Pharma, Inc. 34
Advaxis, Inc. 35
Altor BioScience Corporation 36
Amgen Inc. 37
Ascenta Therapeutics, Inc. 38
Astex Pharmaceuticals, Inc. 39
AstraZeneca Plc 40
AVEO Pharmaceuticals, Inc. 41
BIND Therapeutics, Inc. 42
Boehringer Ingelheim GmbH 43
Bristol-Myers Squibb Company 44
CEL-SCI Corporation 45
Celldex Therapeutics, Inc. 46
Celltrion, Inc. 47
Centrose Llc 48
Critical Outcome Technologies Inc. 49
Daiichi Sankyo Company, Limited 50
Eisai Co., Ltd. 51
Eli Lilly and Company 52
F. Hoffmann-La Roche Ltd. 53
Genentech, Inc. 54
Genexine, Inc. 55
GlaxoSmithKline Plc 56
Gliknik, Inc. 57
Glycotope GmbH 58
ImmunoGen, Inc. 59
Immunomedics, Inc. 60
Immunovative Therapies, Ltd. 61
Incyte Corporation 62
Innate Pharma SA 63
Inovio Pharmaceuticals, Inc. 64
Karyopharm Therapeutics, Inc. 65
Laboratoires Pierre Fabre SA 66
Mabion SA 67
MacroGenics, Inc. 68
MedImmune, LLC 69
Merck & Co., Inc. 70
Merck KGaA 71
Mirati Therapeutics Inc. 72
Molplex Ltd. 73
Novartis AG 74
Oncolytics Biotech Inc. 75
Onconova Therapeutics, Inc. 76
OncoSec Medical Inc. 77
Oncovir, Inc. 78
Ono Pharmaceutical Co., Ltd. 79
OXiGENE, Inc. 80
Panacea Biotec Limited 81
PCI Biotech AS 82
Pfizer Inc. 83
Shionogi & Co., Ltd. 84
Symphogen A/S 85
Synta Pharmaceuticals Corp. 86
Takara Bio Inc. 87
Threshold Pharmaceuticals, Inc. 88
VasGene Therapeutics, Inc. 89
VentiRx Pharmaceuticals, Inc. 90
Virttu Biologics Limited 91
Viventia Biotechnologies Inc. 92
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 93
Assessment by Monotherapy Products 93
Assessment by Combination Products 94
Assessment by Target 95
Assessment by Mechanism of Action 100
Assessment by Route of Administration 104 For more information open Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015.

SKU: GMDHC6515IDB

Original Article: Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...